Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2
Journal of Clinical Oncology2013Vol. 31(23), pp. 2849–2853
Citations Over TimeTop 1% of 2013 papers
Mauro Zukin, Carlos H. Barrios, José Rodrigues Pereira, Ronaldo de Albuquerque Ribeiro, Carlos Augusto de Mendonça Beato, Yeni Neron do Nascimento, André M. Murad, Fábio Franke, Maristela Precivale, Luiz H. Araujo, Clarissa Baldotto, Fernando Meton de Alencar Câmara Vieira, I. A. Small, Carlos Gil Ferreira, Rogério Lilenbaum
Abstract
Combination chemotherapy with CP significantly improves survival in patients with advanced NSCLC and ECOG PS of 2.
Related Papers
- → Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)(2018)12 cited
- → Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy (CRT) for Patients with Locally Advanced Non–small-cell Lung Cancer (LANSCLC): A Phase I Trial(2009)2 cited
- Safety and efficacy in clinical studies on pemetrexed and gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer(2014)
- Clinical study of pemetrexed combined with carboplatin as the first-line treatment of senile patients with advanced non-squamous non-small cell lung cancer(2013)
- → Clinical comparison study on pemetrexed combined with carboplatin versus paclitaxel combined with carboplatin as concurrent chemoradiotherapy in locally advanced non-small cell lung cancer(2013)